Sangamo Therapeutics (SGMOQ) Receivables - Net (2010 - 2025)

Sangamo Therapeutics has reported Receivables - Net for 16 years, with the latest figure at $400000.0 in Q4 2025.

• On a quarterly basis, Receivables - Net fell 23.95% year-over-year to $400000.0 in Q4 2025; TTM through Dec 2025 was $400000.0, a 23.95% decrease from a year earlier, with the FY2025 full-year figure at $400000.0, down 23.95% from the prior year.
• Receivables - Net was $400000.0 for Q4 2025 at Sangamo Therapeutics, down from $523000.0 in the prior quarter.
• The five-year high for Receivables - Net was $10.5 million in Q3 2024, with the low at $366000.0 in Q1 2025.
• Average Receivables - Net over 5 years is $3.7 million, with a median of $3.2 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net soared 814.29% in 2024, then tumbled 95.02% in 2025.
• Over 5 years, Receivables - Net stood at $6.0 million in 2021, then slumped by 38.47% to $3.7 million in 2022, then sank by 75.05% to $923000.0 in 2023, then plunged by 43.01% to $526000.0 in 2024, then fell by 23.95% to $400000.0 in 2025.
• The last three Receivables - Net figures came in at $400000.0 (Q4 2025), $523000.0 (Q3 2025), and $372000.0 (Q2 2025), per Business Quant data.